<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360421</url>
  </required_header>
  <id_info>
    <org_study_id>#Exparel_In_Amputation</org_study_id>
    <nct_id>NCT04360421</nct_id>
  </id_info>
  <brief_title>Use of Long-acting Bupivacaine In Lower Extremity Amputation</brief_title>
  <official_title>Use of Liposomal Bupivacaine (Exparel) In Expedited Recovery Following Lower Extremity Amputation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheela Patel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigator-initiated study is to assess the use of liposomal
      bupivacaine in major extremity amputation and its effects on post-operative opioid narcotic
      use, length of stay, and in-hospital costs. Liposomal bupivacaine is an encapsulated,
      injectable amide anesthetic intended for use in long-acting local anesthesia. It has been
      shown in randomized trials to be effective in reducing post-operative pain while reducing
      opioid narcotic use and length of hospital stay following several surgical procedures,
      particularly after total knee arthroplasty. Extremity amputation is a painful operation often
      performed in seriously ill or debilitated patients, often related to infection, trauma or
      malignancy. Application of liposomal bupivacaine in extremity amputation is not well
      described. We intend to enroll adults greater than age 18 years of age who are to undergo
      major extremity amputation. Patients will receive targeted injections of liposomal
      bupivacaine during their procedure. Patient pain scores, total opioid use, and length of
      hospital stay will be tracked. Patients receiving liposomal bupivicaine will be compared to
      similarly matched subjects who received standard anesthesia regimens without liposomal
      bupivicaine. We hypothesize that liposomal bupivicaine used during major amputation decreases
      opioid use, hospital stay, and in-hospital costs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total opioid use</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Total morphine equivalent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cost of stay</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>US Dollar cost</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Numeric rating scale of 0 to 10, where 0 is no pain and 10 is the worst possible pain.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Amputation</condition>
  <condition>Anesthesia, Local</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Intraoperative liposomal bupivacaine field block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Patient's undergoing major extremity amputation and enrolled in the study as part of the experimental arm will, during their amputation operation, receive liposomal bupivicaine per recommended manufacturing dosing and administration in a &quot;field block&quot; for long-acting local anesthesia.</description>
    <arm_group_label>Intraoperative liposomal bupivacaine field block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Patients who underwent unilateral or bilateral lower extremity major amputation,
             either primary or revision: partial foot, ankle disarticulation, transtibial, knee
             disarticulation, transfemoral [1 year retrospective analysis]

          -  Patients who meet clinical indication for unilateral or bilateral lower extremity
             major amputation, either primary or revision: partial foot, ankle disarticulation,
             transtibial, knee disarticulation, transfemoral

        Exclusion Criteria:

          -  Minor amputations

          -  Liver dysfunction (impaired metabolism of Amides)

          -  Concomitant psychiatric or chronic pain disorders

          -  Pregnancy

          -  Amide anesthetic allergy

          -  Presence of perioperative sepsis or acute organ dysfunction

          -  Need for ICU admission at any point

          -  Polytrauma

          -  Quadriplegic/Paraplegic/Insensate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristyn Mannoia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Department of Vascular Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hans K Boggs, MD</last_name>
    <phone>2099697010</phone>
    <email>haboggs@llu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatriz Leong, MD</last_name>
    <email>beleong@llu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marx Genovez, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Motakef S, Wong WW, Ingargiola MJ, Nguyen D, Galdyn IA, Kim HY, Gupta SC. Liposomal Bupivacaine in Implant-Based Breast Reconstruction. Plast Reconstr Surg Glob Open. 2017 Nov 20;5(11):e1559. doi: 10.1097/GOX.0000000000001559. eCollection 2017 Nov.</citation>
    <PMID>29263963</PMID>
  </reference>
  <reference>
    <citation>Surdam JW, Licini DJ, Baynes NT, Arce BR. The use of exparel (liposomal bupivacaine) to manage postoperative pain in unilateral total knee arthroplasty patients. J Arthroplasty. 2015 Feb;30(2):325-9. doi: 10.1016/j.arth.2014.09.004. Epub 2014 Sep 16.</citation>
    <PMID>25282071</PMID>
  </reference>
  <reference>
    <citation>Hyland SJ, Deliberato DG, Fada RA, Romanelli MJ, Collins CL, Wasielewski RC. Liposomal Bupivacaine Versus Standard Periarticular Injection in Total Knee Arthroplasty With Regional Anesthesia: A Prospective Randomized Controlled Trial. J Arthroplasty. 2019 Mar;34(3):488-494. doi: 10.1016/j.arth.2018.11.026. Epub 2018 Nov 23.</citation>
    <PMID>30554925</PMID>
  </reference>
  <reference>
    <citation>Felling DR, Jackson MW, Ferraro J, Battaglia MA, Albright JJ, Wu J, Genord CK, Brockhaus KK, Bhave RA, McClure AM, Shanker BA, Cleary RK. Liposomal Bupivacaine Transversus Abdominis Plane Block Versus Epidural Analgesia in a Colon and Rectal Surgery Enhanced Recovery Pathway: A Randomized Clinical Trial. Dis Colon Rectum. 2018 Oct;61(10):1196-1204. doi: 10.1097/DCR.0000000000001211.</citation>
    <PMID>30192328</PMID>
  </reference>
  <reference>
    <citation>Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3.</citation>
    <PMID>22900785</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Sheela Patel</investigator_full_name>
    <investigator_title>Assistant Professor, Surgery</investigator_title>
  </responsible_party>
  <keyword>lower extremity amputation</keyword>
  <keyword>liposomal bupivacaine</keyword>
  <keyword>expedited recovery</keyword>
  <keyword>vascular surgery</keyword>
  <keyword>pain management</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

